Ivabradine Eg

Ivabradine Hydrochloride, the active ingredient in Ivabradine Eg, is a heart‑rate‑lowering agent presented as an oral tablet for oral use. It selectively reduces sinus node activity and is employed in the management of chronic heart failure and stable angina in adult patients. GNH USA supplies Ivabradine Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine Hydrochloride is used to modulate heart rate in cardiovascular conditions. - Chronic heart failure: reduces heart rate to improve symptoms and decrease hospitalizations. - Stable angina pectoris: lowers heart rate to relieve angina episodes when beta‑blockers are unsuitable. - Inappropriate sinus tachycardia (off‑label): helps control excessive heart rate when other therapies fail.

Adverse reactions may occur with ivabradine use.

Common Side Effects: - Bradycardia: slowed heart rate, may cause fatigue. - Visual disturbances: luminous phenomena (phosphenes). - Headache: mild to moderate intensity. - Dizziness: especially on standing. - Hypertension: occasional increase in blood pressure. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical attention. - Atrial fibrillation or other arrhythmias. - Severe hypotension leading to syncope. - Persistent visual impairment or retinal issues. - Allergic reactions: rash, angioedema. - Hepatic dysfunction in rare cases.

Before initiating ivabradine, consider the following precautions. - Contraindication: severe hypotension or systolic BP <90 mmHg. - Caution: existing sinus node dysfunction or AV block. - Monitor: heart rate regularly, especially after dose changes. - Avoid: concomitant use with strong CYP3A4 inhibitors without dose adjustment. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store at below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Ivabradine may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine levels. - Concomitant bradycardic agents (beta‑blockers, diltiazem, verapamil): risk of excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly raise plasma concentrations. - Digoxin: monitor for additive effects on cardiac conduction. - Antihypertensives: watch for additive blood‑pressure lowering. - St. John’s wort: may reduce ivabradine exposure, decreasing efficacy.